PWS logo

Pacer WealthShield ETF (PWS)

$31.65

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on PWS

AUM

$23737500

P/E ratio

17.9

Dividend yield

1.4866%

Expense ratio

0.6%

Beta

0.402272

Price on PWS

Previous close

$31.83

Today's open

$31.70

Day's range

$31.63 - $31.70

52 week range

$29.30 - $33.71

Profile about PWS

Headquarters

US

Exchange

CBOE Global Markets BZX

Issue type

Exchange-Traded Fund

PWS industries and sectors

Asset Allocations

Top holdings in PWS

0.02%

ROG:SM

0%

News on PWS

ConSynance Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of CSTI-500 for Prader-Willi Syndrome

RENSSELAER, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc. (“ConSynance”), a clinical-stage biotechnology company developing first-in-class therapies for neurobehavioral symptoms in rare neurodevelopmental disorders, today announced that the first participant has been dosed in its Phase 2a clinical trial of CSTI-500 for Prader-Willi syndrome (PWS), marking a significant clinical development milestone for the program.

news source

GlobeNewsWire • Jun 16, 2026

news preview

Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period

Participants who resumed VYKAT XR following a 16-week randomized withdrawal period demonstrated improvements in hyperphagia and behavioral symptoms as early as Week 13, with benefits continuing through 2 years VYKAT XR demonstrated statistically significant and sustained improvements in hyperphagia and Prader-Willi syndrome-related behaviors for up to 3 years compared to real-world data from the PATH for PWS Natural History Study SAN DIEGO, June 15, 2026 /PRNewswire/ -- Soleno Therapeutics, a Neurocrine Biosciences (Nasdaq: NBIX) company, today announced late-breaking data at ENDO 2026 showing that resuming treatment with VYKAT® XR (diazoxide choline) extended-release tablets for two years after a 16-week randomized withdrawal period was associated with durable improvements in hyperphagia and behavioral symptoms characteristic of Prader-Willi syndrome (PWS).   "These compelling data further reinforce our confidence in VYKAT XR as a safe and effective long-term treatment for hyperphagia in individuals four years of age and older living with Prader-Willi syndrome," said Sanjay Keswani, M.D.

news source

PRNewsWire • Jun 15, 2026

news preview

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --    -- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

news source

GlobeNewsWire • Jun 13, 2026

news preview

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast on Saturday, June 13 at 9:00 a.m. ET/8:00 a.m. CT to discuss interim six-month results from the Company's Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome (PWS).

news source

GlobeNewsWire • Jun 12, 2026

news preview

Saniona Receives Positive Feedback from FDA on Regulatory Path for Tesomet in Prader-Willi Syndrome (PWS)

PRESS RELEASE

news source

GlobeNewsWire • Jun 9, 2020

news preview

Is the Acute ETF & Stock Selloff an 'Overreaction' or Justified?

Wall Street entered into an official bear market on Mar 12. Is this panic selloff an overreaction or justified?

news source

Zacks Investment Research • Mar 13, 2020

news preview

¹ Disclosures

Get started with M1

Invest in Pacer WealthShield ETF

Open an M1 investment account to buy and sell Pacer WealthShield ETF commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in PWS on M1